The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer

Ann Surg Oncol. 2002 Mar;9(2):177-85. doi: 10.1007/BF02557371.

Abstract

Background: Patients with incompletely resected locally advanced and recurrent colon cancers have a dismal prognosis. Since 1981, 100 colon cancer patients have been treated with combination therapy including surgical resection, chemotherapy, and external plus intraoperative radiotherapy.

Methods: A prospective computerized intraoperative radiation database identified patients for this retrospective review. Data collection included patient demographics, tumor and treatment variables, and morbidity, recurrence, and survival statistics.

Results: The mean age was 55.2 years. Follow-up was available for all patients. Fifty-nine patients have died. Median follow-up of survivors was 70.5 months. Twenty-five patients with locally advanced colon cancer had a median survival of 38.2 months and a 5-year survival of 49%. Eleven of these patients are still free of disease. Seventy-three patients treated for recurrent colon carcinoma had a median survival of 33.3 months from the time of recurrence, with a 5-year survival of 24.7%. Twenty-one are alive without evidence of recurrence. The 38 patients with recurrent disease whose disease was completely resected had a 37.4% 5-year survival.

Conclusions: A multimodality approach using en-bloc surgical resection with radiotherapy and chemotherapy affords some patients with locally advanced and recurrent colon cancer a chance for long-term survival.

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Colectomy*
  • Colonic Neoplasms / mortality
  • Colonic Neoplasms / radiotherapy*
  • Colonic Neoplasms / secondary
  • Colonic Neoplasms / therapy
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Fluorouracil / administration & dosage*
  • Humans
  • Intraoperative Care
  • Male
  • Middle Aged
  • Minnesota / epidemiology
  • Proportional Hazards Models
  • Retrospective Studies
  • Salvage Therapy / methods*
  • Survival Rate

Substances

  • Antimetabolites, Antineoplastic
  • Fluorouracil